MAP2K7 and melanoma: The introduction of BRAF-inhibitors like vemurafenib and dabrafenib and MEK-inhibitors (MEKi) like trametinib (TMB) has resulted in significant improvement in clinical outcomes; such therapeutic regimens have remarkably changed the survival statistics of malignant melanomas in recent years [3,4,5].